Sofosbuvir and Velpatasvir, 400 mg/100 mg tablets, 28 tablets: 2x14 blister cards, Rx Only, Manufactured for: Asegua Therapeutics LLC an affiliate of Gilead Sciences, Inc., Foster City, CA 94404, Made in Ireland, NDC# 72626-2701-1
Published April 16, 2025 · Recall initiated: March 7, 2025
Summary
FDA records drug Class II recall D-0313-2025, published April 16, 2025 and initiated March 7, 2025. Recalling firm: ASEGUA THERAPEUTICS LLC; Status: Ongoing; Reported quantity: 18,541 cartons.; Lot: Lot# 24ASV002UA, Exp Date: 6/30/2028. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Defective Container: blister packs not properly sealed resulting in tablets being loose in the carton.
What to do
Voluntary: Firm initiated · Letter
Get an email if SOFOSBUVIR AND VELPATASVIR has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- SOFOSBUVIR AND VELPATASVIR
- Manufacturer
- ASEGUA THERAPEUTICS LLC
- Distributor
- US Nationwide
- Lot
- Lot# 24ASV002UA, Exp Date: 6/30/2028
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAGabapentin Capsules, USP 400 mg, Rx Only, Packaged in a) 500-count bottles, NDC 62756-139-05; b) 1000-countApril 16, 2025
- FDAFenofibrate Capsules 67 mg, USP, 100-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited,April 16, 2025
- FDAGabapentin Capsules, USP 300 mg, Rx Only, Packaged in a) 500-count bottles, NDC 62756-138-05; b) 1000-countApril 16, 2025
- FDAPropafenone Hydrochloride Extended-Release Capsules 225mg, 60-count bottle, Rx Only, Manufactured by: GlenmarkApril 16, 2025
- FDAVenlafaxine Tablets, USP, 75 mg, 100 Tablets, Rx only, Mfg. by: Zydus Lifesciences Ltd, Ahmedabad, India,April 16, 2025
- FDAPropafenone Hydrochloride Extended-Release Capsules 325mg, 60-count bottle, Rx Only Manufactured by: GlenmarkApril 16, 2025
Questions about this recall
Was Sofosbuvir and Velpatasvir, 400 mg/100 mg tablets, 28 tablets: 2x14 blister cards, Rx Only, Manufactured for: Asegua Therapeutics LLC an affiliate of Gilead Sciences, Inc., Foster City, CA 94404, Made in Ireland, NDC# 72626-2701-1 recalled?
Yes. FDA published recall D-0313-2025 on April 16, 2025. Reported hazard: Defective Container: blister packs not properly sealed resulting in tablets being loose in the carton.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: SOFOSBUVIR AND VELPATASVIR.